Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MassmedicaWAR:MSM -4.51%82 EV-to-EBIT is 13.18 as of Aug. 02, 2026, which is 10% below its 10-year median of 14.60. GuruFocus rates WAR:MSM with a GF Score™ of 82/100 and a GF Value™ of zł4.33 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 470 Medical Devices & Instruments companies, Massmedica ranks better than 67.87% on this metric.
The historical rank and industry rank for Massmedica's EV-to-EBIT or its related term are showing as below:
WAR:MSM'
s EV-to-EBIT Range Over the Past 10 Years
Min: 9.61 Med: 14.6 Max: 110.92
Current: 13.18
During the past 10 years, the highest EV-to-EBIT of Massmedica was 110.92. The lowest was 9.61. And the median was 14.60.
WAR:MSM's EV-to-EBIT is ranked better than 67.87% of 470
companies
in the Medical Devices & Instruments industry
Industry Median: 18.85
vs WAR:MSM: 13.18
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Massmedica's Enterprise Value for the quarter that ended in Mar. 2026 was zł18.89 Mil.
Massmedica's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was zł1.63 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Massmedica EV-to-EBIT Related Terms
Massmedica EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Massmedica's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Massmedica's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Massmedica EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Massmedica's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Massmedica's EV-to-EBIT falls into.
Massmedica's current Enterprise Value is zł21.45 Mil.
Massmedica's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was zł1.63 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Massmedica (WAR:MSM) has a EV-to-EBIT of 13.18 as of Aug. 02, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Massmedica and its competitors. This is 10% below median its historical median of 14.60. Over the past decade, Massmedica's EV-to-EBIT has ranged from 9.61 to 110.92. According to the industry distribution chart, Massmedica ranks #151 out of 470 companies in the Medical Devices & Instruments industry, placing it in the top 32.1%.
Is Massmedica's EV-to-EBIT too high?
Massmedica's current EV-to-EBIT of 13.18 is 10% below median its 10-year median of 14.60. Over the past 10 years, this metric has ranged from a low of 9.61 to a high of 110.92. The Medical Devices & Instruments industry median EV-to-EBIT is 18.85. Massmedica's value of 13.18 is 30.1% below this industry median. Based on the distribution chart, Massmedica ranks #151 out of 470 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Massmedica has a GF Score™ of 82/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Massmedica's EV-to-EBIT compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Massmedica ranks #151 out of 470 companies for EV-to-EBIT. This puts Massmedica in the upper half of its industry. The industry median EV-to-EBIT is 18.85. Massmedica's value of 13.18 is 30.1% below this benchmark. Historically, Massmedica's own EV-to-EBIT has ranged from 9.61 to 110.92 over the past decade. While the company's 10-year median is 14.60 vs. the industry median of 18.85, Massmedica has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 18.85, based on 470 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Massmedica's current EV-to-EBIT of 13.18 is 30.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Massmedica and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 18.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Massmedica's current EV-to-EBIT is 13.18, which is 10% below median its own 10-year median of 14.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Massmedica stock overvalued right now?
Based on GuruFocus' analysis, Massmedica (WAR:MSM) is currently considered Modestly Overvalued. The stock's GF Value™ is zł4.33, compared to a current price of zł5.50 — trading 27% above its estimated fair value. The current EV-to-EBIT is 13.18, which is 10% below median its 10-year median of 14.60 and 30.1% below the Medical Devices & Instruments industry median of 18.85. Massmedica's overall GF Score™ is 82/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Massmedica (WAR:MSM), the current EV-to-EBIT is 13.18 as of Aug. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Massmedica (WAR:MSM) Overvalued in 2026?
Based on GuruFocus' analysis, Massmedica stock appears to be overvalued.
The current stock price of zł5.50 is trading 27% above its estimated GF Value™ of zł4.33.
GuruFocus considers Massmedica to be Modestly Overvalued.
Key valuation signals for WAR:MSM:
EV-to-EBIT: 13.18 (10% below median its 10-year median of 14.60)
GF Value™: zł4.33 vs. price of zł5.50 (27% above fair value)
Industry Position: 30.1% below the Medical Devices & Instruments median (#151 of 470)
No single metric tells the full story. See the WAR:MSM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Massmedica SA is operating in the areas of reconstructive, regenerative, anti-aging and aesthetic medicine. It deals in the distribution of implants and other medical materials used in the treatment of diseases of the musculoskeletal system and in regenerative medicine.
82GF Score
Get the complete analysis for WAR:MSM
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:MSM has been successfully added to your 
